- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01460095
Improving Access to HbA1c in Sub Saharan Africa (IA3)
Improving Access to HbA1c Measurement in Sub-Saharan Africa
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
The objective is to determine whether the introduction of routine affordable HbA1c determination with immediate feedback to patients and relevant education in an underserved population without any further intervention on drug supply would significantly improve diabetes control. As this will be an after-versus-before type study, each patient will be his own control.
Study setting The study will be undertaken in 10 existing diabetes care centre in two countries, including 4 regional centers in Guinea, a West African country of 10 millions inhabitants, and 6 regional centers in Cameroon, a Central African country of 18 million inhabitants.
The health districts covered in Guinea are Conakry, Labe, Kankan and Boke each being situated in a different ecological and cultural areas. In Cameroon, the health districts covered are Biyem Assi in Yaoundé, Garoua, Limbe, Ebolowa, Bamenda, Bafoussam also covering the 4 ecological zone of Cameroon.
All these health districts have existing diabetes care centre with trained personnel run in public hospital with prices and medicine affordable to most of the population covered. However, none of these centers have an HbA1c machine, and diabetes control is mainly evaluated using blood glucose, most often fasting.
Target population The aim is to provide the service to all patients followed in the selected centers at low cost however the first eligible 1000 patients will be included in the formal intervention free of charge.
Eligibility All patients with a physician-confirmed diagnosis of diabetes and who have been followed in the diabetes centre for at least one year are eligible Sample size In order to detect a difference of 1 unit (1% glycated haemoglobin) between to samples with a standard deviation of 1.2%, alpha coefficient of 0.001 and 0.8 power using a two-sided test, a minimum population of 80 subjects is required. The minimum sample size if alpha is 0.01 is 55 subjects. We therefore decided a sample size of 100 patients per centre in order to be able to analyze data taking into account center or physician effect. It thus give an overall sample size of 1000 subjects.
Sampling method We will use a systematic sampling, enrolling consecutive eligible patients volunteering to participate until completion of the sample size in each individual centre.
Inclusion All eligible patients, not intending to migrate from the study site within 1 year, and volunteering to participate will be enrolled. At inclusion the following will record of demographic characteristics, past medical history, characteristics of diabetes, evaluation of patient knowledge, and measurement of anthropometric characteristics, blood pressure, haematocrit, HbA1c, and urinary albumin excretion at baseline.
Intervention and follow up:
Data will be collected using a clinical record form designated to this effect. The intervention will consist of the measurement of HbA1c at baseline, 3, and 6 months with immediate feedback to patients and provision of targeted education after each determination, on level, significance, and targets.
Treatment will follow usual guidelines with no additional intervention. Adjustment of treatment will be done by the health care personnel in a treat-to-target fashion. No change in drug supply will be introduced. No specific recommendation will be given concerning the frequency of hospital visit between the study visits at baseline, month 3, 6, and 12. Each centre will continue with usual follow up frequency.
At month 12, we will repeat the evaluation of patient knowledge, and the measurement of anthropometric characteristics, blood pressure, haematocrit, HbA1c, and urinary albumin excretion for comparison to baseline.
Timeframe
- Start date: Month 7
- End of enrollment: Month 12
- End of follow-up of last patient enrolled: Month 24
Outcome measures
Primary outcome: Change in HbA1c from baseline to 12 months
Secondary outcomes:
- Change in percentage of patients at HbA1c target from baseline to 12 months
- Change in urinary albumin excretion from baseline to 12 months The other measures will serve for the interpretation of data Deliverables
- Dataset for each centre between Month 24 and Month 26
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
-
Boke, Guinea
- Boke Regional Hospital
-
Conakry, Guinea
- CHU Donka
-
Kankan, Guinea
- Kankan Regional Hospital
-
Labe, Guinea
- Labe regional Hospital
-
-
-
-
-
Bafoussam, Kamerun
- Bafoussam District Hospital
-
-
Centre
-
Yaounde, Centre, Kamerun
- Yaoundé Central Hospital
-
-
North
-
Garoua, North, Kamerun
- Garoua Regional Hospital
-
-
North West
-
Bamenda, North West, Kamerun
- Bamenda Regional Hospital
-
-
South West
-
Buea, South West, Kamerun
- Buea Regional Hospital
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Confirmed diabetes mellitus irrespective of type
- Patients who have been followed regularly for at least one year prior to inclusion in the target health facilities
- Adult age (18 years and over)
Exclusion Criteria:
- Individuals planning to migrate from study sites within one year
- Any intercurrent acute illness
- Enrollment in any other concomitant intervention study
Studijní plán
Jak je studie koncipována?
Detaily designu
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: HbA1c measurement and education
3-monthly Hba1c determination with immediate feedback and targeted education delivered to all participants
|
three-monthly point of care measurement of HbA1c with immediate feedback to patients and provision of interpretation and targeted one-to-one education
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
one year change in glycated haemoglobin (HbA1c)
Časové okno: Baseline and 12 months
|
Baseline to 12 months individual change in HbA1c level
|
Baseline and 12 months
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
One-year change in proportion of patients reaching HbA1c targets
Časové okno: Baseline and 12 months
|
Baseline to 12 months change in proportion of patients reaching HbA1c targets in each participating centre and in the overall population
|
Baseline and 12 months
|
One-year change in urinary albumin excretion
Časové okno: Baseline and 12 months
|
Baseline to 12 months individual change in early morning sample urinary albumin excretion
|
Baseline and 12 months
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Eugene Sobngwi, MD, PhD, Newcastle University, UK and Yaounde Central Hospital, Cameroon
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další identifikační čísla studie
- LT07-135 (International Diabetes Federation)
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na HbA1c measurement and education
-
Rigshospitalet, DenmarkFrederiksberg University Hospital; Defactum, Central Denmark RegionAktivní, ne nábor
-
University of ArkansasNational Institute on Minority Health and Health Disparities (NIMHD)NáborCukrovka typu 2Spojené státy
-
Memorial Hospital of Rhode IslandNational Heart, Lung, and Blood Institute (NHLBI)DokončenoKoronární onemocnění | Hypercholesterolémie | Primární zdravotní péče | Management, rizikoSpojené státy
-
University of ArizonaNábor
-
NYU Langone HealthNational Institute on Minority Health and Health Disparities (NIMHD)Zatím nenabírámeCukrovka typu 2Spojené státy
-
University of ArkansasNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Nábor
-
Psychiatric Research Unit, Region Zealand, DenmarkStaženoPsychiatrická hospitalizace
-
University of ArkansasStaženoDiabetes mellitus, typ 2 | Spánková hygienaSpojené státy
-
Sinai Health SystemNáborDiabetes mellitus, typ 2 | Diabetes Mellitus | Diabetes | Diabetes mellitus, typ 1Spojené státy